Latest Posts:

Sorry, no posts matched your criteria.

Follow Us:

Back To Top

Founder of Scalpel featured in Forbes on state of play of AI in UK’s healthcare

October 1st, 2019

In the recent report published by Microsoft it was found that “U.K. healthcare is actually at the forefront of AI innovation”. As the founder of an emerging healthtech startup, Yesh shares: “In my experience, the best way to achieve adoption of AI technology is to introduce frontline clinicians, patients and policymakers in the very early stages of product development. I’ve only found a few hospitals in the U.K. so far that really understand the potential of AI at its core. They are our torchbearers and we’re piloting at six such hospitals to demonstrate improved levels of patient safety.”

Read the full story here.

Image credit: Forbes

Founder of Scalpel featured in Forbes on state of play of AI in UK’s healthcare

October 1st, 2019

In the recent report published by Microsoft it was found that “U.K. healthcare is actually at the forefront of AI innovation”. As the founder of an emerging healthtech startup, Yesh shares: “In my experience, the best way to achieve adoption of AI technology is to introduce frontline clinicians, patients and policymakers in the very early stages of product development. I’ve only found a few hospitals in the U.K. so far that really understand the potential of AI at its core. They are our torchbearers and we’re piloting at six such hospitals to demonstrate improved levels of patient safety.”

Read the full story here.

Image credit: Forbes

Our Food & Agri sector lead featured in Financial Times

September 30th, 2019

“If, as the environmentalists argue, there were a 75 per cent chance of a huge asteroid slamming into Earth in 2050 then we would surely mobilise all our resources today to prevent such a catastrophe. Why do we not respond to global warming with similar urgency?” Edward Perello, Associate Director for Food and Agriculture at DSV says “the biggest challenge is to grow solutions fast enough to deal with the magnitude of the problem.”…

Read the full story here.

Our Food & Agri sector lead featured in Financial Times

September 30th, 2019

“If, as the environmentalists argue, there were a 75 per cent chance of a huge asteroid slamming into Earth in 2050 then we would surely mobilise all our resources today to prevent such a catastrophe. Why do we not respond to global warming with similar urgency?” Edward Perello, Associate Director for Food and Agriculture at DSV says “the biggest challenge is to grow solutions fast enough to deal with the magnitude of the problem.”…

Read the full story here.

The leading independent funder of cancer research, Cancer Research UK, announces our partnership to tackle the complexity of cancer

September 25th, 2019

“The field of oncology is a good example of how our model could improve the impact of science. While there are incredibly talented people working in the field, the sector still suffers from many of the broader challenges in pharmaceuticals, including the dependence on a linear pathway from grant application to discovery, venture and into the clinic. This partnership allows us to bring together the outstanding research capability of Cancer Research UK’s network with DSV’s model of rapidly exploring the cross-disciplinary potential of science, in order to address the complexity presented by cancer.” – Mark Hammond, Founding Director at DSV. Read the full story here.

Image credit: Cancer Research UK

The leading independent funder of cancer research, Cancer Research UK, announces our partnership to tackle the complexity of cancer

September 25th, 2019

“The field of oncology is a good example of how our model could improve the impact of science. While there are incredibly talented people working in the field, the sector still suffers from many of the broader challenges in pharmaceuticals, including the dependence on a linear pathway from grant application to discovery, venture and into the clinic. This partnership allows us to bring together the outstanding research capability of Cancer Research UK’s network with DSV’s model of rapidly exploring the cross-disciplinary potential of science, in order to address the complexity presented by cancer.” – Mark Hammond, Founding Director at DSV. Read the full story here.

Image credit: Cancer Research UK

Our Energy Sector lead shares lessons learnt from the cleantech boom & bust on VentureBeat

September 9th, 2019

Climate change is our biggest existential threat. This is the energy sector’s last chance to get clean tech right. However it’s clear these past mistakes that hope and new technology alone won’t be enough to bend our climate trajectory. The key constraint for any venture-backable company in the energy sector is the requirement it can succeed in the economic status-quo. Rising oil prices, imposition of carbon taxes, or other external factors should serve to strengthen the business case, not justify it in the first place. Rear the full piece here.

Image credit: Floaria Bicher/Getty

Our Energy Sector lead shares lessons learnt from the cleantech boom & bust on VentureBeat

September 22nd, 2019

Climate change is our biggest existential threat. This is the energy sector’s last chance to get clean tech right. However it’s clear these past mistakes that hope and new technology alone won’t be enough to bend our climate trajectory. The key constraint for any venture-backable company in the energy sector is the requirement it can succeed in the economic status-quo. Rising oil prices, imposition of carbon taxes, or other external factors should serve to strengthen the business case, not justify it in the first place. Rear the full piece here.

Image credit: Floaria Bicher/Getty

Antiverse part of the 29 U.K.’s Most Exciting AI Startups on Forbes

September 9th, 2019

Antibodies are the workhorse of therapeutics, used across all diseases from cancer to Alzhiemers. Yet the process of developing them is still pretty haphazard and likely misses high potential candidates. Antiverse uses a combination of deep learning and high-throughput data generation to predict the optimal amino acid sequence for any given anti-gen almost instantly. Full list of startups here.

Antiverse part of the 29 U.K.’s Most Exciting AI Startups on Forbes

September 9th, 2019

Antibodies are the workhorse of therapeutics, used across all diseases from cancer to Alzhiemers. Yet the process of developing them is still pretty haphazard and likely misses high potential candidates. Antiverse uses a combination of deep learning and high-throughput data generation to predict the optimal amino acid sequence for any given anti-gen almost instantly. Full list of startups here.

Optic Earth wins TechX Performance Award of £55,000

Image credit: OGTC

August 30th, 2019

“We’re extremely proud to contribute to the energy transition through venture creation in partnership with the OGTC. The TechX programme is a best-in-class accelerator programme, leading the energy sector. There is nowhere else in the world that offers such profound, tailored and guided access to the most valuable customers in the market” – Dom Falcao, Founding Director at DSV. Read the full story here.

Optic Earth wins TechX Performance Award of £55,000

Image credit: OGTC

August 30th, 2019

“We’re extremely proud to contribute to the energy transition through venture creation in partnership with the OGTC. The TechX programme is a best-in-class accelerator programme, leading the energy sector. There is nowhere else in the world that offers such profound, tailored and guided access to the most valuable customers in the market” – Dom Falcao, Founding Director at DSV. Read the full story here.

Scalpel featured on The HS. Health-Tech Podcast

August 30th, 2019

7 million patients suffer from preventable surgical errors every year. The team at Scalpel are on a mission to make surgery safer. Learn more about the reality and the future of operating rooms via The HS. Health-Tech Podcast.

Podcast link here.

Scalpel featured on The HS. Health-Tech Podcast

August 30th, 2019

7 million patients suffer from preventable surgical errors every year. The team at Scalpel are on a mission to make surgery safer. Learn more about the reality and the future of operating rooms via The HS. Health-Tech Podcast.

Podcast link here.

Holy Grail featured in Techcrunch on building better batteries

August 16th, 2019

‘Do you want to take a step back and see if there’s a better way to do this?’ is the question with which you start your journey at DSV. Just over a year ago, Nuno set out to challenge the status quo in energy storage and build batteries that could actually outperform fossil fuels. Today, Holy Grail has $14 million in letters of intent with potential customers and is expecting to close additional financing as it exits Y Combinator. Read their story covered by TechCrunch here.

Image credit: Holy Grail

Holy Grail featured in Techcrunch on building better batteries

August 16th, 2019

‘Do you want to take a step back and see if there’s a better way to do this?’ is the question with which you start your journey at DSV. Just over a year ago, Nuno set out to challenge the status quo in energy storage and build batteries that could actually outperform fossil fuels. Today, Holy Grail has $14 million in letters of intent with potential customers and is expecting to close additional financing as it exits Y Combinator. Read their story covered by TechCrunch here.

Image credit: Holy Grail

DSV Featured in Forbes on how deep tech start-ups help avoid climate catastrophe

July 29th, 2019

Just over half way through the year as a planet we’ve already used the entire global resources (fish, forest, carbon) that the earth can produce / balance for the year, from this point on we are out of balance and accumulating waste and destruction. This day keeps moving earlier every year and represents an easy to understand measure of our impact on the planet. 

In this article in Forbes, Gemma Milne looks at what deep-tech startups can do to start pushing back this day in the other direction and explores the challenges they face. Featuring commentary on the challenge from our team and portfolio companies. These challenges are explored in further detail under our energy transition and agri theses

Image credit: Tobias Schwarz/AFP/Getty Images

DSV Featured in Forbes on how deep tech start-ups help avoid climate catastrophe

July 29th, 2019

Just over half way through the year as a planet we’ve already used the entire global resources (fish, forest, carbon) that the earth can produce / balance for the year, from this point on we are out of balance and accumulating waste and destruction. This day keeps moving earlier every year and represents an easy to understand measure of our impact on the planet. 

In this article in Forbes, Gemma Milne looks at what deep-tech startups can do to start pushing back this day in the other direction and explores the challenges they face. Featuring commentary on the challenge from our team and portfolio companies. These challenges are explored in further detail under our energy transition and agri theses

Image credit: Tobias Schwarz/AFP/Getty Images

Our AMR lead’s work on automated antibiotic discovery featured in Pharma Times

July 19th, 2019

Prior to joining DSV and ultimately spinning out CC Bio, Matt undertook ground breaking work at the University of Manchester in which they engineered the common gut bacteria E-coli to recreate antibiotic production pathways found in a specific class of soil bacteria. This is important because whilst the antibiotic pathways open up exciting new opportunities the soil dwelling organism is near impossible to work with in automated systems.  

This work has been under wraps but is being published today and is covered by the Pharma Times and has since informed the approach that we are taking with CC Bio

Dr Matthew Cummings, image credit: AstraZaneca

Our AMR lead’s work on automated antibiotic discovery featured in Pharma Times

July 19th, 2019

Prior to joining DSV and ultimately spinning out CC Bio, Matt undertook ground breaking work at the University of Manchester in which they engineered the common gut bacteria E-coli to recreate antibiotic production pathways found in a specific class of soil bacteria. This is important because whilst the antibiotic pathways open up exciting new opportunities the soil dwelling organism is near impossible to work with in automated systems.  

This work has been under wraps but is being published today and is covered by the Pharma Times and has since informed the approach that we are taking with CC Bio

Dr Matthew Cummings, image credit: AstraZaneca

DSV engineering teams get to hang out with the Ferrari family in Italy

June, 2019

Sometimes work can be a lot of fun. We were honoured to be asked by the family that own Ferrari and Fiat to bring together our favourite deep-tech startups both within and outside DSV and head over to Italy for the SEI Torino Forum. Portfolio companies including Holy Grail.ai and The Engineering Company (stealth) got to network with the CTO of Ferrari and the likes of Josh from Lux amongst a host of other deep-tech investors and industry contacts, roll on next summer!

Video credit: SEI

DSV engineering teams get to hang out with the Ferrari family in Italy

June, 2019

Sometimes work can be a lot of fun. We were honoured to be asked by the family that own Ferrari and Fiat to bring together our favourite deep-tech startups both within and outside DSV and head over to Italy for the SEI Torino Forum. Portfolio companies including Holy Grail.ai and The Engineering Company (stealth) got to network with the CTO of Ferrari and the likes of Josh from Lux amongst a host of other deep-tech investors and industry contacts, roll on next summer!

Video credit: SEI

Discussing the mindset and experiences that drive science entrepreneurship on the Science Disrupt podcast

June 29th, 2019

On this podcast one of our founders Dominic discusses what sort of experiences, behaviours and mindsets drive people to want to make a change and avoid getting trapped in the status quo. Also featuring one of our favourite academic partners Davide Danovi, Director of King’s ‘Stem Cell Hotel’. 

Podcast link here.

Discussing the mindset and experiences that drive science entrepreneurship on the Science Disrupt podcast

June 29th, 2019

On this podcast one of our founders Dominic discusses what sort of experiences, behaviours and mindsets drive people to want to make a change and avoid getting trapped in the status quo. Also featuring one of our favourite academic partners Davide Danovi, Director of King’s ‘Stem Cell Hotel’. 

Podcast link here.

DSV teams CC Bio and Reflection Therapeutics win Babraham and AstraZeneca Exchange, again 😉

May 21st, 2019

Last year Antiverse walked away with the top prize at the Accelerate Babraham competition, this year there were more prizes and DSV teams Reflection Therapeutics and CC Bio both walked away with the big cheques. We’re not generally a fan of competitions and would rather teams focus on building but we’re always happy to see teams take a moment out for Babraham with it’s absolutely top class panel from SV Health, Medixci and Draper Esprit and world class follow on support and facilities. 

One Nucleus article announcing winners here.

Image credit: AstraZeneca

DSV teams CC Bio and Reflection Therapeutics win Babraham and AstraZeneca Exchange, again 😉

May 21st, 2019

Last year Antiverse walked away with the top prize at the Accelerate Babraham competition, this year there were more prizes and DSV teams Reflection Therapeutics and CC Bio both walked away with the big cheques. We’re not generally a fan of competitions and would rather teams focus on building but we’re always happy to see teams take a moment out for Babraham with it’s absolutely top class panel from SV Health, Medixci and Draper Esprit and world class follow on support and facilities. 

One Nucleus article announcing winners here.

Image credit: AstraZeneca

Cytera featured in Techcrunch and Labiotech’s Top 10 Young Biotechs

December 5th, 2018

A key pillar of our Pharma thesis is that scientific R&D can only overcome many of its current challenges with much higher levels of automation to improve repeatability and the speed and scale of exploration. Portfolio company Cytera is making this happen by automating one of the most widely used, repeated and sensitive operations in the lab – growing and maintaining cells. 

Techrunch recently published a video covering why their approach is a step forward from existing automation, Labiotech also published an even more in depth interview and ranked them amongst the most exciting young biotech startups in Europe

Image credit: Cytera Cellworks

Cytera featured in Techcrunch and Labiotech’s Top 10 Young Biotechs

December 5th, 2018

A key pillar of our Pharma thesis is that scientific R&D can only overcome many of its current challenges with much higher levels of automation to improve repeatability and the speed and scale of exploration. Portfolio company Cytera is making this happen by automating one of the most widely used, repeated and sensitive operations in the lab – growing and maintaining cells. 

Techrunch recently published a video covering why their approach is a step forward from existing automation, Labiotech also published an even more in depth interview and ranked them amongst the most exciting young biotech startups in Europe

Image credit: Cytera Cellworks

Discussing the role of angel investing in ending age related diseases

October 3rd, 2018

The field of aging related disease or ‘longevity’ has been around for 30+ years but not taken particularly seriously by mainstream science due to a small number of advocates making rather inflated claims. Over the last few years however a much wider pool of researchers, industry and finance has begun to realise that pretty much all non-infectious diseases are age related diseases, they occur because something has broken over time. Even more shockingly patching up any ‘one’ of them, would make very little difference to average life span, likely as little as 2 years. Because of this the focus is shifting to how to address the underlying mechanisms of failure that are common across disease, we cover this in more detail in our Pharma thesis.

The major challenge of this is that in the main the research funders have little interest in this area and industry considers it too disconnected from near term results, this leaves a research and translational funding gap in an area of immense societal and financial opportunity. In this panel at the Ending Age Related Diseases conference we discussed how angel investment is best deployed across the longevity opportunity space.  

Full conference panel summary and video.

Video credit: Life Extension Advocacy Foundadtion

Discussing the role of angel investing in ending age related diseases

October 3rd, 2018

The field of aging related disease or ‘longevity’ has been around for 30+ years but not taken particularly seriously by mainstream science due to a small number of advocates making rather inflated claims. Over the last few years however a much wider pool of researchers, industry and finance has begun to realise that pretty much all non-infectious diseases are age related diseases, they occur because something has broken over time. Even more shockingly patching up any ‘one’ of them, would make very little difference to average life span, likely as little as 2 years. Because of this the focus is shifting to how to address the underlying mechanisms of failure that are common across disease, we cover this in more detail in our Pharma thesis.

The major challenge of this is that in the main the research funders have little interest in this area and industry considers it too disconnected from near term results, this leaves a research and translational funding gap in an area of immense societal and financial opportunity. In this panel at the Ending Age Related Diseases conference we discussed how angel investment is best deployed across the longevity opportunity space.  

Full conference panel summary and video.

Video credit: Life Extension Advocacy Foundadtion

DSV announced as the UK and Scotland’s venture builder for Clean Hydrocarbons

July 30th, 2018

The major challenge with facilitating the energy transition towards cleanpower isn’t that the technology or finance isn’t there, it’s innovator’s dilemma at every level, within organisations, within financiers and at governmental levels. The Oil and Gas industry represents a significant part of the UK economy and is many times larger in other countries, those jobs can’t simply disappear overnight. Because of this, we strongly believe that we should focus on working with incumbents to orchestrate a more rapid transition. 

To this end, we have partnered with the Oil and Gas Technology Council to create Europe’s first venture builder focused on identifying opportunities to both significantly reduce carbon emissions whilst growing the economies that are dependent on energy extraction and generation. The partnership was covered by Energy Voice. You can also read more on our thinking on Clean Hydrocarbons here.

DSV announced as the UK and Scotland’s venture builder for Clean Hydrocarbons

July 30th, 2018

The major challenge with facilitating the energy transition towards cleanpower isn’t that the technology or finance isn’t there, it’s innovator’s dilemma at every level, within organisations, within financiers and at governmental levels. The Oil and Gas industry represents a significant part of the UK economy and is many times larger in other countries, those jobs can’t simply disappear overnight. Because of this, we strongly believe that we should focus on working with incumbents to orchestrate a more rapid transition. 

To this end, we have partnered with the Oil and Gas Technology Council to create Europe’s first venture builder focused on identifying opportunities to both significantly reduce carbon emissions whilst growing the economies that are dependent on energy extraction and generation. The partnership was covered by Energy Voice. You can also read more on our thinking on Clean Hydrocarbons here.

Antiverse seed round headed up by founder of $2.5bn antibody giant Abcam

August, 2018

Antibodies are the workhorse of therapeutics, used across all diseases from cancer to Alzhiemers. Yet the process of developing them is still pretty haphazard and likely misses high potential candidates. Antiverse uses a combination of deep learning and high-throughput data generation to predict the optimal amino acid sequence for any given anti-gen almost instantly. 

The round was led by the UK Science and Innovation fund which specialises in synthetic biology alongside Jonathan Milner who founded antibody specalist Abcam, now valued at over $2.5bn. Jonathan started Abcam after discovering the need for better antibodies during his PhD so is well aware of the potential of working with commercially minded researchers. 

Jonathan Milner, image credit: Labiotech.eu

Antiverse seed round headed up by founder of $2.5bn antibody giant Abcam

August, 2018

Antibodies are the workhorse of therapeutics, used across all diseases from cancer to Alzhiemers. Yet the process of developing them is still pretty haphazard and likely misses high potential candidates. Antiverse uses a combination of deep learning and high-throughput data generation to predict the optimal amino acid sequence for any given anti-gen almost instantly. 

The round was led by the UK Science and Innovation fund which specialises in synthetic biology alongside Jonathan Milner who founded antibody specalist Abcam, now valued at over $2.5bn. Jonathan started Abcam after discovering the need for better antibodies during his PhD so is well aware of the potential of working with commercially minded researchers. 

Jonathan Milner, image credit: Labiotech.eu

DSV featured in Forbes article on best practice in building science start-ups

August 8th, 2018

We’re always talking about how starting with a discovery is often the hardest way to start a science company as you are fixed on the asset not the opportunity. 

In the article Gemma explores the options for building science startups, how we think about this at DSV and how venture builders can help you to forge a more effective route.

DSV featured in Forbes article on best practice in building science start-ups

August 8th, 2018

We’re always talking about how starting with a discovery is often the hardest way to start a science company as you are fixed on the asset not the opportunity. 

In the article Gemma explores the options for building science startups, how we think about this at DSV and how venture builders can help you to forge a more effective route.

DSV speaks at SXSW: What if starting a science venture was as easy as starting a digital venture?

Image credit: SXSW

May 18th, 2018

Alongside our friends at Science Disrupt, Unit DX and Science Practice we were invited to SXSW to explore how to create effective science entrepreneurship communities. The panel covered physical spaces, programmes, venture creation and virtual communities. 

A full write up from Science Practice can be found here. 

DSV speaks at SXSW: What if starting a science venture was as easy as starting a digital venture?

Image credit: SXSW

May 18th, 2018

Alongside our friends at Science Disrupt, Unit DX and Science Practice we were invited to SXSW to explore how to create effective science entrepreneurship communities. The panel covered physical spaces, programmes, venture creation and virtual communities. 

A full write up from Science Practice can be found here. 

DSV asked to inform the UK’s life science strategy

December 21st, 2017

A couple of weeks ago we were invited to Parliament to provide evidence to inform the government’s Life Science Strategy. That is the aim to generate four biotech companies worth more than £2bn in the next 10 years. 

The principal focus of the report is on ‘scaling up’ but with almost no focus on the venture creation end. Given our position that we are already missing out on enormous opportunities due to the linear development path from grant>paper>asset>venture this is something we sought to address and to our delight was included in the final report. 

Labiotech published our position here.

The final report is available here.

Image credit: GOV.UK

DSV asked to inform the UK’s life science strategy

December 21st, 2017

A couple of weeks ago we were invited to Parliament to provide evidence to inform the government’s Life Science Strategy. That is the aim to generate four biotech companies worth more than £2bn in the next 10 years. 

The principal focus of the report is on ‘scaling up’ but with almost no focus on the venture creation end. Given our position that we are already missing out on enormous opportunities due to the linear development path from grant>paper>asset>venture this is something we sought to address and to our delight was included in the final report. 

Labiotech published our position here.

The final report is available here.

Image credit: GOV.UK

DSV featured in Nature Jobs blog

September 5th, 2016

Starting a company is often considered one of the riskiest things you can do when in reality the opposite is true. Even where things go wrong the experiences and network gained often catapult an academic career forward by years.

In this issue of Nature Jobs we cover the pros, cons and examples of how exploring the world of science startups has impacted academic careers.

DSV featured in Nature Jobs blog

September 5th, 2016

Starting a company is often considered one of the riskiest things you can do when in reality the opposite is true. Even where things go wrong the experiences and network gained often catapult an academic career forward by years.

In this issue of Nature Jobs we cover the pros, cons and examples of how exploring the world of science startups has impacted academic careers.